Menopur And Rekovelle Combination Study Version 2.0
NCT06997900
Recruiting
The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is: - Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ? Researchers will compare the new dosing regimen to the MARCS study re... Read More
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
07/29/2025
Locations: Ottawa fertility centre, Ottawa, Ontario +1 locations
Conditions: IVF, Controlled Ovarian Simulation, Fertility Disorders
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migrain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Central Research Associates, Birmingham, Alabama +109 locations
Conditions: Episodic Migraine
Register for Updates
Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
NCT06156176
Recruiting
Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Parkwood Hospital - St. Joseph's Health Care London, London, Ontario
Conditions: Long-COVID, Post-COVID-19 Syndrome, Post-COVID Syndrome, Fatigue, Long COVID-19, Post COVID-19 Condition, Post-COVID Condition
Register for Updates
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168
Recruiting
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Florida Cancer Specialists, Sarasota, Florida +23 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Local Institution - 0066, Birmingham, Alabama +46 locations
Conditions: Lung Cancer
Register for Updates
Trifecta-Lung cfDNA-MMDx Study
NCT05837663
Recruiting
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT, Phoenix, Arizona +11 locations
Conditions: Lung Transplantation
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +98 locations
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
NCT06109948
Recruiting
Study ABX1100-1001 is a first-in-human (FIH), phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) and multiple doses (MD) of ABX1100 administered intravenously to healthy participants and patients with LOPD. * Part A features a SAD study with a double-blind, placebo-controlled, randomized design in NHVs involving 3 cohorts (A1-A3). This Part also includes a single dose, open-labeled cohort (A4) in NHVs which will commence afte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: UCI, Orange, California +4 locations
Conditions: Healthy, Late Onset Pompe Disease
Register for Updates
Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial
NCT05820126
Recruiting
This is a pilot trial to discover the feasibility of recruiting 50 pts over the course of 12 months. The trial is testing the efficacy of using cold-stored vs. room temperature stored (current standard of care) platelets to treat bleeding in persons with hematological disorders and thrombocytopenia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The Ottawa Hospital - General Campus, Ottawa, Ontario
Conditions: Hematologic Malignancy
Register for Updates
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: City of Hope, Duarte, California +28 locations
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Register for Updates
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
NCT05508464
Recruiting
This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: London Health Sciences Centre- London Regional Cancer Program, London, Ontario
Conditions: Metastatic Cancer
Register for Updates
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Arizona Liver Health, Tucson, Arizona +147 locations
Conditions: Primary Biliary Cholangitis (PBC)
Register for Updates